Polycysticovarysyndrome,PCOSPolycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in women of childbearing age, with an incidence of aboutapproximately 6% to 10% in women of childbearing age. The main clinical features are chronic anovulation, oligomenorrhea or amenorrhea, multiple cystic follicles under ovarian ultrasound examination, hyperandrogenemia and infertility. In addition to reproductive abnormalities, PCOS patients often observeexhibit obesity, insulin resistance with compensatory hyperinsulinemia, dyslipidemia, type 2 diabetes and an increased risk of cardiovascular disease. At present, the pathogenesis of PCOS is not clear, lack ofandeffective prevention and treatment methodsare lacking.

  In recent years, Professor Zhou Xu's research group has carried out in-depth and systematic research on the treatment and pathogenesis of PCOS. In this study, we used thea rat model to observe its therapeutic effect on PCOS from the point of view of Adiposeadipose-derived mesenchymal stemcells（AMSCs）cells (AMSCs) for the first time, and deeply analyzed the molecular mechanism.

  It has been found that AMSCs can significantly improve the symptoms of PCOS. The mechanism is that AMSC activates the p-IRS1 and p-AKT pathways by releasing the exocrine targeting Btg2 gene carrying miR-21-5p, which promotes the glucose uptake of hepatocytes, and finally achieves the effect of treating PCOS. The results provide a new idea for stem cells to be used in theclinical treatment of PCOS and lay a theoretical foundation for the prevention and treatment of animal follicular cysts.

  The research results are published in the biomaterial Top journal Biomaterials (IF:15.304). Cao Maosheng, a doctoral student in the research group, is the first author, and Professor Zhou Xu and Professor Li Chunjin are the communication authors.

  https://www.sciencedirect.com/science/article/pii/S0142961222003799